240 results on '"Wang, Liang-Chuan"'
Search Results
2. A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade
3. Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
4. Abstract 2936: INCA33890, a novel PD-1×TGFꞵR2 bispecific antibody conditionally antagonizes TGFꞵ signaling in primary immune cells co-expressing PD-1
5. Supplementary Table from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
6. Supplementary Data from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
7. Supplementary Figure from Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor
8. Data from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
9. Data from Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
10. Supplemental Figure 6 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
11. Supplemental Figure 7 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
12. Supplementary Figure Legend from Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
13. Supplementary Methods from Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
14. Supplemental Figure 3 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
15. Supplemental Figure 1 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
16. Supplementary Figures 1 - 9 from Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity
17. Supplemental Figure 5 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
18. Supplemental Figure 4 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
19. Supplemental Figure Legends from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
20. Supplemental Figure 2 from Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
21. Data from Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
22. Supplementary Table 2 from Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors
23. Supplementary Methods from Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors
24. Supplementary Figures 1 - 5 from Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors
25. Supplementary Table 1 from Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor–Transduced Human T cells in Solid Tumors
26. Supplementary Figures S1-S4 from Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor
27. Supplementary Figure 6 from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
28. Supplementary Table 1 from CCL2 Blockade Augments Cancer Immunotherapy
29. Supplementary Figure Legend 1 from CCL2 Blockade Augments Cancer Immunotherapy
30. Supplementary Figure 8 from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
31. Supplementary Figure 2 from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
32. Supplementary Figure 3 from Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
33. Data from Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
34. Supplementary Figure 3 from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
35. Supplementary Figure 1 from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
36. Supplementary Figure 2 from CCL2 Blockade Augments Cancer Immunotherapy
37. Data from CCL2 Blockade Augments Cancer Immunotherapy
38. Supplementary Figure 4 from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
39. Supplementary Figure 5 from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
40. Supplementary Table 1 from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
41. Supplementary Materials and Methods from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
42. Data from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
43. Supplementary Figure Legend from Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
44. Supplementary Figure 1 from Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
45. Supplementary Figure 1 from CCL2 Blockade Augments Cancer Immunotherapy
46. Supplementary Figure Legends from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
47. Supplementary Figure Legend 2 from CCL2 Blockade Augments Cancer Immunotherapy
48. Supplementary Figure 2 from Enhanced Effector Responses in Activated CD8+ T Cells Deficient in Diacylglycerol Kinases
49. Supplementary Figure 7 from Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
50. Thymidylate Synthase and Folyl-Polyglutamate Synthase Are Not Clinically Useful Markers of Response to Pemetrexed in Patients with Malignant Pleural Mesothelioma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.